Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer-Reference-Cited by-同舟云学术

Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer

Published:2019-02-12 Issue:1 Volume:9 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Martin Nikolas Tim,Roy Dominic Guy,Workenhe Samuel Tekeste,van den Wollenberg Diana J. M.^ORCID,Hoeben Rob C.^ORCID,Mossman Karen Louise,Bell John Cameron^ORCID,Bourgeois-Daigneault Marie-Claude

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-018-38385-7.pdf

Reference23 articles.

1. Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559–67 (2014).

2. Workenhe, S. T. & Mossman, K. L. Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies. Mol. Ther. 22, 251–256 (2014).

3. Diaconu, I. et al. Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. Cancer Res. 72, 2327–2338 (2012).

4. Donnelly, O. G. et al. Measles virus causes immunogenic cell death in human melanoma. Gene Ther. 20, 7–15 (2013).

5. Miyamoto, S. et al. Coxsackievirus B3 Is an Oncolytic Virus with Immunostimulatory Properties That Is Active against Lung Adenocarcinoma. Cancer Res. 72, 2609–2621 (2012).

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer;Vaccines;2024-08-23

2. Revolutionizing Breast Cancer Care: Cutting-Edge Breakthroughs and Future Frontiers in Precision Medicine;Interdisciplinary Cancer Research;2024

3. Increased expression of the immunoproteasome subunits PSMB8 and PSMB9 by cancer cells correlate with better outcomes for triple-negative breast cancers;Scientific Reports;2023-02-06

4. Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer;Cancers;2022-12-23

5. pH-responsive nanoprodrugs combining a Src inhibitor and chemotherapy to potentiate antitumor immunity via pyroptosis in head and neck cancer;Acta Biomaterialia;2022-12